Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30016552,Overall response rate,"Overall response rate (complete remission [CR], CR with incomplete hematological recovery [CRi], partial remission [PR], marrow CR) in the MDS/CMML subgroups was 32% and in the AML subgroup (CR/CRi/PR) was 22%.",Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30016552/),%,32,23216,DB00928,Azacitidine
,30016552,Overall response rate,"Overall response rate (complete remission [CR], CR with incomplete hematological recovery [CRi], partial remission [PR], marrow CR) in the MDS/CMML subgroups was 32% and in the AML subgroup (CR/CRi/PR) was 22%.",Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30016552/),%,22,23217,DB00928,Azacitidine
,17564707,maximum observed plasma concentration (Cmax),"The mean maximum observed plasma concentration (Cmax), 64.8-77.0 ng/ml, and the mean area under the plasma concentration-time curve (AUC0-infinity), 152-163 ng h/ml, were unchanged during dosing of decitabine for 3 days.",Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564707/),[ng] / [ml],64.8-77.0,28257,DB00928,Azacitidine
,17564707,area under the plasma concentration-time curve (AUC0-infinity),"The mean maximum observed plasma concentration (Cmax), 64.8-77.0 ng/ml, and the mean area under the plasma concentration-time curve (AUC0-infinity), 152-163 ng h/ml, were unchanged during dosing of decitabine for 3 days.",Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564707/),[h·ng] / [ml],152-163,28258,DB00928,Azacitidine
,17564707,terminal phase elimination half-life,"The mean values for terminal phase elimination half-life (0.62-0.78 h), total body clearance (125-132 l/h per m2), and volume of distribution at steady state (62.7-89.2 l/m2), remained unchanged during the every 8 h dosing (P>0.05).",Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564707/),h,0.62-0.78,28259,DB00928,Azacitidine
,17564707,total body clearance,"The mean values for terminal phase elimination half-life (0.62-0.78 h), total body clearance (125-132 l/h per m2), and volume of distribution at steady state (62.7-89.2 l/m2), remained unchanged during the every 8 h dosing (P>0.05).",Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564707/),[l] / [h·m2],125-132,28260,DB00928,Azacitidine
,17564707,volume of distribution at steady state,"The mean values for terminal phase elimination half-life (0.62-0.78 h), total body clearance (125-132 l/h per m2), and volume of distribution at steady state (62.7-89.2 l/m2), remained unchanged during the every 8 h dosing (P>0.05).",Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564707/),[l] / [m2],62.7-89.2,28261,DB00928,Azacitidine
,2425959,peak plasma concentrations,"For 75 and 100 mg/m2 given as 1-h infusions, mean peak plasma concentrations of 0.93 and 2.01 microM, respectively, were attained.",Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2425959/),μM,0.93,31094,DB00928,Azacitidine
,2425959,peak plasma concentrations,"For 75 and 100 mg/m2 given as 1-h infusions, mean peak plasma concentrations of 0.93 and 2.01 microM, respectively, were attained.",Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2425959/),μM,2.01,31095,DB00928,Azacitidine
,2425959,peak plasma drug concentrations,"In one case at 30 mg/m2 and another at 60 mg/m2, peak plasma drug concentrations were determined to be 0.244 and 0.409 microM, respectively.",Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2425959/),μM,0.244,31096,DB00928,Azacitidine
,2425959,peak plasma drug concentrations,"In one case at 30 mg/m2 and another at 60 mg/m2, peak plasma drug concentrations were determined to be 0.244 and 0.409 microM, respectively.",Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2425959/),μM,0.409,31097,DB00928,Azacitidine
,2425959,t1/2 alpha,"Following cessation of the infusion rapid disappearance of drug from plasma was observed with a t1/2 alpha and t1/2 beta of 7 and 35 min, respectively.",Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2425959/),min,7,31098,DB00928,Azacitidine
,2425959,t1/2 beta,"Following cessation of the infusion rapid disappearance of drug from plasma was observed with a t1/2 alpha and t1/2 beta of 7 and 35 min, respectively.",Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2425959/),min,35,31099,DB00928,Azacitidine
,18221921,limit of detection,"The limit of detection was determined as 1.0 and 0.125ngml(-1) and lower limits of quantitation were 10 and 1ngml(-1) for decitabine and SAHA, respectively.","Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18221921/),1/[ngml],1.0,33544,DB00928,Azacitidine
,18221921,limit of detection,"The limit of detection was determined as 1.0 and 0.125ngml(-1) and lower limits of quantitation were 10 and 1ngml(-1) for decitabine and SAHA, respectively.","Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18221921/),1/[ngml],0.125,33545,DB00928,Azacitidine
,18221921,limit of detection,"The limit of detection was determined as 1.0 and 0.125ngml(-1) and lower limits of quantitation were 10 and 1ngml(-1) for decitabine and SAHA, respectively.","Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18221921/),1/[ngml],10,33546,DB00928,Azacitidine
,18221921,limit of detection,"The limit of detection was determined as 1.0 and 0.125ngml(-1) and lower limits of quantitation were 10 and 1ngml(-1) for decitabine and SAHA, respectively.","Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18221921/),1/[ngml],1,33547,DB00928,Azacitidine
,25933833,half-life,"Oral ilorasertib pharmacokinetics appeared dose proportional, with a 15-hour half-life and no interaction with azacitidine.","Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25933833/),h,15,38360,DB00928,Azacitidine
,30926081,AUCs,"Decitabine 30 mg and 40 mg plus cedazuridine 100 mg produced mean day-5 decitabine AUCs (146 ng × h/mL for decitabine 30 mg, and 221 ng × h/mL for decitabine 40 mg) closest to the mean intravenous-decitabine AUC (164 ng × h/mL).","An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30926081/),[h·ng] / [ml],146,39270,DB00928,Azacitidine
,30926081,AUCs,"Decitabine 30 mg and 40 mg plus cedazuridine 100 mg produced mean day-5 decitabine AUCs (146 ng × h/mL for decitabine 30 mg, and 221 ng × h/mL for decitabine 40 mg) closest to the mean intravenous-decitabine AUC (164 ng × h/mL).","An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30926081/),[h·ng] / [ml],221,39271,DB00928,Azacitidine
,30926081,AUC,"Decitabine 30 mg and 40 mg plus cedazuridine 100 mg produced mean day-5 decitabine AUCs (146 ng × h/mL for decitabine 30 mg, and 221 ng × h/mL for decitabine 40 mg) closest to the mean intravenous-decitabine AUC (164 ng × h/mL).","An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30926081/),[h·ng] / [ml],164,39272,DB00928,Azacitidine
,23822717,oral bioavailability,"However, it exhibits a low oral bioavailability (only 9% in mice), because of low permeability across the intestine membrane and rapid metabolism to inactive metabolite.",A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23822717/),%,9,47461,DB00928,Azacitidine
,23822717,IC50,"The uptake of Gly-Sar by Caco-2 cells could be competitively inhibited by compounds 4a and 4c, with IC50 being 2.20 ± 0.28 mM and 3.46 ± 0.16 mM, respectively.",A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23822717/),mM,2.20,47462,DB00928,Azacitidine
,23822717,IC50,"The uptake of Gly-Sar by Caco-2 cells could be competitively inhibited by compounds 4a and 4c, with IC50 being 2.20 ± 0.28 mM and 3.46 ± 0.16 mM, respectively.",A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23822717/),mM,3.46,47463,DB00928,Azacitidine
,23822717,oral absolute bioavailability,"The oral absolute bioavailability of DAC was 46.7%, 50.9%, and 26.9% after compounds 4a, 4c, and DAC were orally administered to rats at a dose of 15 mg/kg, respectively.",A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23822717/),%,46.7,47464,DB00928,Azacitidine
,23822717,oral absolute bioavailability,"The oral absolute bioavailability of DAC was 46.7%, 50.9%, and 26.9% after compounds 4a, 4c, and DAC were orally administered to rats at a dose of 15 mg/kg, respectively.",A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23822717/),%,50.9,47465,DB00928,Azacitidine
,23822717,oral absolute bioavailability,"The oral absolute bioavailability of DAC was 46.7%, 50.9%, and 26.9% after compounds 4a, 4c, and DAC were orally administered to rats at a dose of 15 mg/kg, respectively.",A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23822717/),%,26.9,47466,DB00928,Azacitidine
,23822717,bioavailability,The bioavailability of compounds 4a and 4c in rats was both reduced to about 32% when orally coadministrated with typical hPepT1 substrate Gly-Sar (150 mg/kg).,A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23822717/),%,32,47467,DB00928,Azacitidine
,2455594,t1/2 alpha,"The plasma elimination of AAC is rapid and characterized by a triphasic decay with t1/2 alpha = 3.6-5.4 min, t1/2 beta = 18-24 min, and t1/2 gamma = 94-144 min for the above infusion schedules.",Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2455594/),min,3.6-5.4,56139,DB00928,Azacitidine
,2455594,t1/2 beta,"The plasma elimination of AAC is rapid and characterized by a triphasic decay with t1/2 alpha = 3.6-5.4 min, t1/2 beta = 18-24 min, and t1/2 gamma = 94-144 min for the above infusion schedules.",Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2455594/),min,18-24,56140,DB00928,Azacitidine
,2455594,t1/2 gamma,"The plasma elimination of AAC is rapid and characterized by a triphasic decay with t1/2 alpha = 3.6-5.4 min, t1/2 beta = 18-24 min, and t1/2 gamma = 94-144 min for the above infusion schedules.",Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2455594/),min,94-144,56141,DB00928,Azacitidine
,2455594,CSF:plasma Css ratio,The CSF penetration of AAC as measured by the CSF:plasma Css ratio for the 12-h infusion was 0.15.,Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2455594/),,0.15,56142,DB00928,Azacitidine
,29282890,Response rate,"Response rate was 96%, driven primarily by stable disease (94%); one patient achieved complete remission.","Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29282890/),%,96,61248,DB00928,Azacitidine
,29282890,Maximum plasma concentration (Cmax ),"Maximum plasma concentration (Cmax ) was higher in Chinese patients; however, mean azacitidine exposure (1190 ng·h/mL) was similar to the North American cohort (1021 ng·h/mL).","Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29282890/),[h·ng] / [ml],1190,61249,DB00928,Azacitidine
,29282890,Maximum plasma concentration (Cmax ),"Maximum plasma concentration (Cmax ) was higher in Chinese patients; however, mean azacitidine exposure (1190 ng·h/mL) was similar to the North American cohort (1021 ng·h/mL).","Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29282890/),[h·ng] / [ml],1021,61250,DB00928,Azacitidine
,29282890,exposure,"Maximum plasma concentration (Cmax ) was higher in Chinese patients; however, mean azacitidine exposure (1190 ng·h/mL) was similar to the North American cohort (1021 ng·h/mL).","Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29282890/),[h·ng] / [ml],1190,61251,DB00928,Azacitidine
,29282890,exposure,"Maximum plasma concentration (Cmax ) was higher in Chinese patients; however, mean azacitidine exposure (1190 ng·h/mL) was similar to the North American cohort (1021 ng·h/mL).","Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29282890/),[h·ng] / [ml],1021,61252,DB00928,Azacitidine
,24668305,plasma half-life,Evaluation of in vivo plasma concentrations and pharmacokinetic properties of SGI-110 showed rapid conversion to decitabine and a plasma half-life of 4 hr.,SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24668305/),h,4,62353,DB00928,Azacitidine
,26442612,TI,"RBC TI rates were similar with both dosing schedules (31% and 38%, respectively).",Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26442612/),,31,64158,DB00928,Azacitidine
,26442612,TI,"RBC TI rates were similar with both dosing schedules (31% and 38%, respectively).",Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26442612/),,38,64159,DB00928,Azacitidine
,18548103,bioavailability,"Subjects safely tolerated 80 mg, a dose for which the mean bioavailability was 17.4% of historic s.c. exposure.",A pilot pharmacokinetic study of oral azacitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18548103/),%,17.4,66766,DB00928,Azacitidine
,1717216,terminal half-life,"Following the infusion, plasma levels declined triphasically with a terminal half-life of 5.7 +/- 2.0 hr.",Clinical pharmacology of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) following 72-hour infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1717216/),h,5.7,75394,DB00928,Azacitidine
,1717216,AUC,When the various doses were normalized to 1.75 mg/m2/hr (the maximum tolerated dose as determined from the phase I trial) the mean AUC value was 4232 +/- 987 (ng/ml)hr.,Clinical pharmacology of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) following 72-hour infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1717216/),[ng] / [ml)hr],4232,75395,DB00928,Azacitidine
,1717216,CPss,"Also, when normalized, the mean CPss was 58 +/- 13 ng/ml, which is within the reported concentration range necessary for inhibiting malignant cell growth.",Clinical pharmacology of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) following 72-hour infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1717216/),[ng] / [ml],58,75396,DB00928,Azacitidine
,1717216,Total clearance,"Total clearance was rapid, 528 +/- 138 ml/(m2.min), and not dose-related.",Clinical pharmacology of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) following 72-hour infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1717216/),[ml] / [m2·min],528,75397,DB00928,Azacitidine
,9815635,minimum target concentration,Steady-state plasma concentrations exceeded the minimum target concentration of 2 microgram/ml in all patients who received >/=78 mg/m2/h for 24 h.,Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815635/),[μg] / [ml],2,76937,DB00928,Azacitidine
,9815635,steady-state clearance,The mean steady-state clearance was 475 +/- 103 ml/min/m2 and did not change with dose.,Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815635/),[ml] / [m2·min],475,76938,DB00928,Azacitidine
,2468469,biological half-life,"The survey of the drug elimination from blood is of a two-phase character: the first phase--with a biological half-life of 5.5 min (for rats) and 6.5 min (for rabbits); the second phase--1.2 and 2.5 h, respectively.",[Pharmacokinetic characteristics of 6-azacytidine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468469/),min,5.5,79266,DB00928,Azacitidine
,2468469,biological half-life,"The survey of the drug elimination from blood is of a two-phase character: the first phase--with a biological half-life of 5.5 min (for rats) and 6.5 min (for rabbits); the second phase--1.2 and 2.5 h, respectively.",[Pharmacokinetic characteristics of 6-azacytidine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468469/),min,6.5,79267,DB00928,Azacitidine
,2468469,biological half-life,"The survey of the drug elimination from blood is of a two-phase character: the first phase--with a biological half-life of 5.5 min (for rats) and 6.5 min (for rabbits); the second phase--1.2 and 2.5 h, respectively.",[Pharmacokinetic characteristics of 6-azacytidine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468469/),h,1.2,79268,DB00928,Azacitidine
,2468469,biological half-life,"The survey of the drug elimination from blood is of a two-phase character: the first phase--with a biological half-life of 5.5 min (for rats) and 6.5 min (for rabbits); the second phase--1.2 and 2.5 h, respectively.",[Pharmacokinetic characteristics of 6-azacytidine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468469/),h,2.5,79269,DB00928,Azacitidine
,30988610,Drug loading into,Drug loading into nanocarriers of 27.45±0.05 nm was 5.8±0.5 mg/mL.,Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30988610/),[mg] / [ml],5.8,101803,DB00928,Azacitidine
,19051502,plasma half-life,"The plasma half-life after iv injection was 3.5 hours; after sc administration, the plasma half-life was 4.2 hours.","Absorption, distribution, and excretion of 5-azacytidine (NSC-102816) in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051502/),h,3.5,104247,DB00928,Azacitidine
,19051502,plasma half-life,"The plasma half-life after iv injection was 3.5 hours; after sc administration, the plasma half-life was 4.2 hours.","Absorption, distribution, and excretion of 5-azacytidine (NSC-102816) in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051502/),h,4.2,104248,DB00928,Azacitidine
,19051502,maximum level of radioactivity,The maximum level of radioactivity detected in the spinal fluid was equivalent to 0.2 microg of 5-azacytidine per milliliter of fluid.,"Absorption, distribution, and excretion of 5-azacytidine (NSC-102816) in man. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051502/),μg,0.2,104249,DB00928,Azacitidine
,15831784,bioavailability (AUC),"The exposure profiles following SC drug administration illustrate measurable azacitidine levels with bioavailability (AUC) values within 89% of those measured following IV administration (range, 70%-112%).",Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831784/),%,89,106166,DB00928,Azacitidine
,15831784,bioavailability (AUC),"The exposure profiles following SC drug administration illustrate measurable azacitidine levels with bioavailability (AUC) values within 89% of those measured following IV administration (range, 70%-112%).",Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831784/),%,112,106167,DB00928,Azacitidine
,15831784,IV half-life,The median IV half-life was 0.36 +/- 0.02 hours compared to 0.69 +/- 0.14 hours for SC administration.,Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831784/),h,0.36,106168,DB00928,Azacitidine
,15831784,IV half-life,The median IV half-life was 0.36 +/- 0.02 hours compared to 0.69 +/- 0.14 hours for SC administration.,Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831784/),h,0.69,106169,DB00928,Azacitidine
,30563881,overall survival,"The median overall survival for patients on study was 7.9 months (95% confidence interval, 4.1-not reached).",Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30563881/),month,7.9,120993,DB00928,Azacitidine
,21576646,relative oral bioavailability,Mean relative oral bioavailability ranged from 6.3% to 20%.,"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21576646/),%,6.3,125498,DB00928,Azacitidine
,21576646,relative oral bioavailability,Mean relative oral bioavailability ranged from 6.3% to 20%.,"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21576646/),%,20,125499,DB00928,Azacitidine
,21576646,Overall response rate,"Overall response rate (i.e., complete remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in previously untreated patients.","Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21576646/),%,35,125500,DB00928,Azacitidine
,21576646,Overall response rate,"Overall response rate (i.e., complete remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in previously untreated patients.","Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21576646/),%,73,125501,DB00928,Azacitidine
,28841236,maximum tolerated dose,The maximum tolerated dose was 120 mg and the recommended phase 2 dose was 60 mg.,Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28841236/),mg,120,137859,DB00928,Azacitidine
,57000,"half-life (t1/2, beta phase)","After bolus, plasma 14C levels exhibited as multiphasic disappearance pattern; half-life (t1/2, beta phase) = 3.4 to 6.2 hr.",The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/57000/),h,3.4 to 6.2,137867,DB00928,Azacitidine
,57000,t1/2,"At 20 degrees in Ringer's lactate (pH 6.2), the t1/2 was 94 to 100 hr.",The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/57000/),h,94 to 100,137868,DB00928,Azacitidine
,6184151,half-lives,"After an i.v. bolus, the plasma disappearance of 5-aza-dCyd was biphasic with half-lives of 5 and 43 min in rabbits and of 5 and 75 min in dogs.",Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6184151/),min,5,142046,DB00928,Azacitidine
,6184151,half-lives,"After an i.v. bolus, the plasma disappearance of 5-aza-dCyd was biphasic with half-lives of 5 and 43 min in rabbits and of 5 and 75 min in dogs.",Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6184151/),min,43,142047,DB00928,Azacitidine
,6184151,half-lives,"After an i.v. bolus, the plasma disappearance of 5-aza-dCyd was biphasic with half-lives of 5 and 43 min in rabbits and of 5 and 75 min in dogs.",Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6184151/),min,75,142048,DB00928,Azacitidine
,6184151,apparent volume of distribution at steady state,The apparent volume of distribution at steady state was in the order of 800 ml/kg for both species.,Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6184151/),[ml] / [kg],800,142049,DB00928,Azacitidine
,6184151,total plasma clearance,The total plasma clearance of the drug was 15 ml/min/kg in rabbits and 9 ml/min/kg in dogs.,Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6184151/),[ml] / [kg·min],15,142050,DB00928,Azacitidine
,6184151,total plasma clearance,The total plasma clearance of the drug was 15 ml/min/kg in rabbits and 9 ml/min/kg in dogs.,Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6184151/),[ml] / [kg·min],9,142051,DB00928,Azacitidine
,6184151,slow disappearance half-lives,"After a 180 min i.v. infusion, 5-aza-dCyd slow disappearance half-lives were of 39 min in rabbits and of 144 min in dogs.",Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6184151/),min,39,142052,DB00928,Azacitidine
,6184151,slow disappearance half-lives,"After a 180 min i.v. infusion, 5-aza-dCyd slow disappearance half-lives were of 39 min in rabbits and of 144 min in dogs.",Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6184151/),min,144,142053,DB00928,Azacitidine
,23789936,absolute oral bioavailability,Mean absolute oral bioavailability ranged from 13·9% (fed) to 34·8% (fasting) in 12 patients treated at the 560 mg b.i.d. dose level.,Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23789936/),%,13·9,143544,DB00928,Azacitidine
,23789936,absolute oral bioavailability,Mean absolute oral bioavailability ranged from 13·9% (fed) to 34·8% (fasting) in 12 patients treated at the 560 mg b.i.d. dose level.,Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23789936/),%,34·8,143545,DB00928,Azacitidine
,21624006,bioavailability,"The bioavailability of azacitidine following subcutaneous administration was 91.1%, indicating that azacitidine is nearly completely absorbed after subcutaneous administration.",Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21624006/),%,91.1,151310,DB00928,Azacitidine
,6206020,t1/2 alpha,"The half-lives corresponding to the three exponential phases were: t1/2 alpha = 5.78 min, t1/2 beta = 1.57 h and t1/2 gamma = 22.0 h in dog 1 and t1/2 alpha = 7.41 min, t1/2 beta = 2.25 h and t1/2 gamma = 21.6 h in dog 2.","Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6206020/),min,5.78,156459,DB00928,Azacitidine
,6206020,t1/2 beta,"The half-lives corresponding to the three exponential phases were: t1/2 alpha = 5.78 min, t1/2 beta = 1.57 h and t1/2 gamma = 22.0 h in dog 1 and t1/2 alpha = 7.41 min, t1/2 beta = 2.25 h and t1/2 gamma = 21.6 h in dog 2.","Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6206020/),h,1.57,156460,DB00928,Azacitidine
,6206020,t1/2 gamma,"The half-lives corresponding to the three exponential phases were: t1/2 alpha = 5.78 min, t1/2 beta = 1.57 h and t1/2 gamma = 22.0 h in dog 1 and t1/2 alpha = 7.41 min, t1/2 beta = 2.25 h and t1/2 gamma = 21.6 h in dog 2.","Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6206020/),h,22.0,156461,DB00928,Azacitidine
,6206020,t1/2 alpha,"The half-lives corresponding to the three exponential phases were: t1/2 alpha = 5.78 min, t1/2 beta = 1.57 h and t1/2 gamma = 22.0 h in dog 1 and t1/2 alpha = 7.41 min, t1/2 beta = 2.25 h and t1/2 gamma = 21.6 h in dog 2.","Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6206020/),min,7.41,156462,DB00928,Azacitidine
,6206020,t1/2 beta,"The half-lives corresponding to the three exponential phases were: t1/2 alpha = 5.78 min, t1/2 beta = 1.57 h and t1/2 gamma = 22.0 h in dog 1 and t1/2 alpha = 7.41 min, t1/2 beta = 2.25 h and t1/2 gamma = 21.6 h in dog 2.","Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6206020/),h,2.25,156463,DB00928,Azacitidine
,6206020,t1/2 gamma,"The half-lives corresponding to the three exponential phases were: t1/2 alpha = 5.78 min, t1/2 beta = 1.57 h and t1/2 gamma = 22.0 h in dog 1 and t1/2 alpha = 7.41 min, t1/2 beta = 2.25 h and t1/2 gamma = 21.6 h in dog 2.","Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6206020/),h,21.6,156464,DB00928,Azacitidine
,2408749,Total-body clearance,Total-body clearance of 311 +/- 76 ml/min/sq m and postinfusion half-lives between 1 and 2 h were observed.,A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2408749/),[ml] / [m·min·sq],311,156809,DB00928,Azacitidine
,2408749,half-lives,Total-body clearance of 311 +/- 76 ml/min/sq m and postinfusion half-lives between 1 and 2 h were observed.,A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2408749/),h,1 and 2,156810,DB00928,Azacitidine
,32951163,MTD,Dose-limiting toxicity was reported in one patient in cycle 1; the MTD of volasertib in combination with decitabine was determined as 400 mg.,Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32951163/),mg,400,157397,DB00928,Azacitidine
,32951163,Objective response rate,Objective response rate was 23%.,Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32951163/),%,23,157398,DB00928,Azacitidine
,17020984,maximum tolerated dose,The maximum tolerated dose of DAC was 60 to 75 mg/m(2) depending on the number of prior cytotoxic chemotherapy regimens.,"Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17020984/),[mg] / [m(2],60 to 75,171466,DB00928,Azacitidine
,32036412,Tmax,"Median Tmax was reached at 2 h and 1 h post-dose in fed and fasted states, respectively (P < 0.001).",Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32036412/),h,2,174683,DB00928,Azacitidine
,32036412,Tmax,"Median Tmax was reached at 2 h and 1 h post-dose in fed and fasted states, respectively (P < 0.001).",Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32036412/),,1,174684,DB00928,Azacitidine
,23172636,overall survival (OS),The median overall survival (OS) was 12.4 months; the 1-year OS rate was 56%.,Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23172636/),month,12.4,175244,DB00928,Azacitidine
,29500276,overall response rate (ORR),"Three patients had a partial response (PR), and 6 patients had stable disease (SD) >3 months, for an overall response rate (ORR) and clinical benefit rate of 15% and 45%, respectively.","A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29500276/),%,15,180172,DB00928,Azacitidine
,29500276,clinical benefit rate,"Three patients had a partial response (PR), and 6 patients had stable disease (SD) >3 months, for an overall response rate (ORR) and clinical benefit rate of 15% and 45%, respectively.","A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29500276/),%,45,180173,DB00928,Azacitidine
,32203138,OS,Median (95% CI) OS was 5.36 (4.27-7.95) months for combination therapy versus 7.26 (6.47-8.64) months for decitabine alone (hazard ratio: 1.04; 95% CI: 0.79-1.37; p = 0.78).,"Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32203138/),month,5.36,180692,DB00928,Azacitidine
,32203138,OS,Median (95% CI) OS was 5.36 (4.27-7.95) months for combination therapy versus 7.26 (6.47-8.64) months for decitabine alone (hazard ratio: 1.04; 95% CI: 0.79-1.37; p = 0.78).,"Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32203138/),month,7.26,180693,DB00928,Azacitidine
,1705165,Plasma steady-state concentrations,Plasma steady-state concentrations of ara-AC were reached in all patients within 4-6 h and ranged from 1.1 microM (11 mg/m2/h for 24 h) to 7.5 microM (54.5 mg/m2/h for 24 h).,Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1705165/),μM,1.1,180791,DB00928,Azacitidine
,1705165,Plasma steady-state concentrations,Plasma steady-state concentrations of ara-AC were reached in all patients within 4-6 h and ranged from 1.1 microM (11 mg/m2/h for 24 h) to 7.5 microM (54.5 mg/m2/h for 24 h).,Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1705165/),mg,11,180792,DB00928,Azacitidine
,1705165,Plasma steady-state concentrations,Plasma steady-state concentrations of ara-AC were reached in all patients within 4-6 h and ranged from 1.1 microM (11 mg/m2/h for 24 h) to 7.5 microM (54.5 mg/m2/h for 24 h).,Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1705165/),μM,7.5,180793,DB00928,Azacitidine
,1705165,Plasma steady-state concentrations,Plasma steady-state concentrations of ara-AC were reached in all patients within 4-6 h and ranged from 1.1 microM (11 mg/m2/h for 24 h) to 7.5 microM (54.5 mg/m2/h for 24 h).,Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1705165/),[mg] / [h·m2],54.5,180794,DB00928,Azacitidine
,1705165,total body clearance,"The mean total body clearance of ara-AC for 47 courses, levels 1-7, was 592 +/- 147 (SD) ml/min/m2 which is similar to prior pharmacokinetic data from the 24-h and 72-h infusion trials of the Pediatric and Medicine Branches, respectively.",Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1705165/),[ml] / [m2·min],592,180795,DB00928,Azacitidine
,2475244,Plasma steady-state concentrations,"Plasma steady-state concentrations of fazarabine were attained by 2-4 h in all patients and were 1.8 and 2.5 microM at the 15- and 20-mg/m2/h doses, respectively.",Phase I trial and pharmacokinetic evaluation of fazarabine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475244/),μM,1.8,195347,DB00928,Azacitidine
,2475244,Plasma steady-state concentrations,"Plasma steady-state concentrations of fazarabine were attained by 2-4 h in all patients and were 1.8 and 2.5 microM at the 15- and 20-mg/m2/h doses, respectively.",Phase I trial and pharmacokinetic evaluation of fazarabine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475244/),μM,2.5,195348,DB00928,Azacitidine
,2475244,total body clearance,"The total body clearance of fazarabine was 571 and 550 ml/min/m2 at the 15- and 20-mg/m2/h doses, respectively.",Phase I trial and pharmacokinetic evaluation of fazarabine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475244/),[ml] / [m2·min],571,195349,DB00928,Azacitidine
,2475244,total body clearance,"The total body clearance of fazarabine was 571 and 550 ml/min/m2 at the 15- and 20-mg/m2/h doses, respectively.",Phase I trial and pharmacokinetic evaluation of fazarabine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475244/),[ml] / [m2·min],550,195350,DB00928,Azacitidine
,2475244,Steady-state CSF concentrations,Steady-state CSF concentrations ranged from 0.29 to 0.74 microM in these three individuals and the steady-state CSF:plasma ratios ranged from 0.22-0.25.,Phase I trial and pharmacokinetic evaluation of fazarabine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475244/),μM,0.29 to 0.74,195351,DB00928,Azacitidine
,2475244,steady-state CSF:plasma ratios,Steady-state CSF concentrations ranged from 0.29 to 0.74 microM in these three individuals and the steady-state CSF:plasma ratios ranged from 0.22-0.25.,Phase I trial and pharmacokinetic evaluation of fazarabine in children. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475244/),,0.22-0.25,195352,DB00928,Azacitidine
,2475244,steady-state concentrations,Both the plasma and CSF steady-state concentrations were within the 0.1 to 1 microM range reported to be cytotoxic in vitro against the Molt-4 human T-lymphoblastic leukemia cell line.,Phase I trial and pharmacokinetic evaluation of fazarabine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475244/),μM,0.1 to 1,195353,DB00928,Azacitidine
,7505267,CSF clearance,"Disappearance from the cerebrospinal fluid (CSF) was biexponential, and CSF clearance was 0.2 ml/min, which exceeds the rate of CSF bulk flow by 5-fold.","Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytosine (fazarabine, NSC 281272) in the nonhuman primate. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7505267/),[ml] / [min],0.2,198111,DB00928,Azacitidine
up to,29042320,circulation time,Our pharmacokinetic studies revealed that intravenously administered BTNPs increased circulation time up to 3days.,Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29042320/),d,3,199721,DB00928,Azacitidine
,31331399,Response rate,"Response rate to guadecitabine was 17% (2 complete remission (CR), 3 CR with incomplete blood count recovery (CRi), or CR with incomplete platelets recovery (CRp)) in the phase I component and 23% (14 CR, 9 CRi/CRp) in phase II.",Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31331399/),%,17,201605,DB00928,Azacitidine
,31331399,Response rate,"Response rate to guadecitabine was 17% (2 complete remission (CR), 3 CR with incomplete blood count recovery (CRi), or CR with incomplete platelets recovery (CRp)) in the phase I component and 23% (14 CR, 9 CRi/CRp) in phase II.",Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31331399/),%,23,201606,DB00928,Azacitidine
,31331399,response rate,"Gene expression clustering defined a subset of patients (~ 20%) that had (i) high DNMT3B and low CDKN2B, CTCF, and CDA expression; (ii) enrichment for KRAS/NRAS mutations; (iii) frequent CpG island hypermethylation; (iv) low long interspersed nuclear element 1 (LINE-1) hypomethylation after treatment; and (v) resistance to guadecitabine in both phase I (response rate 0% vs. 33%, p = 0.07) and phase II components of the study (response rate 5% vs. 30%, p = 0.02).",Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31331399/),%,0,201607,DB00928,Azacitidine
,31331399,response rate,"Gene expression clustering defined a subset of patients (~ 20%) that had (i) high DNMT3B and low CDKN2B, CTCF, and CDA expression; (ii) enrichment for KRAS/NRAS mutations; (iii) frequent CpG island hypermethylation; (iv) low long interspersed nuclear element 1 (LINE-1) hypomethylation after treatment; and (v) resistance to guadecitabine in both phase I (response rate 0% vs. 33%, p = 0.07) and phase II components of the study (response rate 5% vs. 30%, p = 0.02).",Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31331399/),%,33,201608,DB00928,Azacitidine
,31331399,response rate,"Gene expression clustering defined a subset of patients (~ 20%) that had (i) high DNMT3B and low CDKN2B, CTCF, and CDA expression; (ii) enrichment for KRAS/NRAS mutations; (iii) frequent CpG island hypermethylation; (iv) low long interspersed nuclear element 1 (LINE-1) hypomethylation after treatment; and (v) resistance to guadecitabine in both phase I (response rate 0% vs. 33%, p = 0.07) and phase II components of the study (response rate 5% vs. 30%, p = 0.02).",Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31331399/),%,5,201609,DB00928,Azacitidine
,31331399,response rate,"Gene expression clustering defined a subset of patients (~ 20%) that had (i) high DNMT3B and low CDKN2B, CTCF, and CDA expression; (ii) enrichment for KRAS/NRAS mutations; (iii) frequent CpG island hypermethylation; (iv) low long interspersed nuclear element 1 (LINE-1) hypomethylation after treatment; and (v) resistance to guadecitabine in both phase I (response rate 0% vs. 33%, p = 0.07) and phase II components of the study (response rate 5% vs. 30%, p = 0.02).",Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31331399/),%,30,201610,DB00928,Azacitidine
,33190437,OS,"The median time of treatment was 6 cycles, and the median OS was 16.1 months (95%CI 10.9-20.6 months).","[Efficacy and safety of generic azacitidine in Chinese patients with higher-risk myelodysplastic syndromes: a multicenter, prospective, single-arm study]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33190437/),month,16.1,212537,DB00928,Azacitidine
,33190437,OS,"For 36 patients(50%)received treatment at ≥6 cycles, and the median OS was 22.3 months(95%CI 16.1- not evaluative).","[Efficacy and safety of generic azacitidine in Chinese patients with higher-risk myelodysplastic syndromes: a multicenter, prospective, single-arm study]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33190437/),month,22.3,212538,DB00928,Azacitidine
,1688736,Plasma steady-state levels,Plasma steady-state levels ranged from 0.13 to 0.6 microM for doses of 1.25 to 5.94 mg/m2/h.,"Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688736/),μM,0.13 to 0.6,213696,DB00928,Azacitidine
,1688736,total body clearance,Mean total body clearance was 647 ml/min/m2.,"Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688736/),[ml] / [m2·min],647,213697,DB00928,Azacitidine
,15851763,T(max),5-AC was rapidly absorbed with the mean T(max) occurring at 0.47 hour.,Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15851763/),h,0.47,216141,DB00928,Azacitidine
,15851763,maximum concentration (C(max)),"Average maximum concentration (C(max)) and area under the curve (AUC(0-infinity)) values increased in a dose-proportionate manner with increasing dose from 10 to 75 mg/m2/d; the mean +/- SD C(max) and AUC(0-infinity) at 10 mg/m2/d were 776 +/- 459 nM and 1,355 +/- 1,125 h*nM, respectively, and at 75 mg/m2/d were 4,871 +/- 1,398 nM and 6,582 +/- 2,560 h*nM, respectively.",Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15851763/),nM,776,216142,DB00928,Azacitidine
,15851763,maximum concentration (C(max)),"Average maximum concentration (C(max)) and area under the curve (AUC(0-infinity)) values increased in a dose-proportionate manner with increasing dose from 10 to 75 mg/m2/d; the mean +/- SD C(max) and AUC(0-infinity) at 10 mg/m2/d were 776 +/- 459 nM and 1,355 +/- 1,125 h*nM, respectively, and at 75 mg/m2/d were 4,871 +/- 1,398 nM and 6,582 +/- 2,560 h*nM, respectively.",Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15851763/),nM,"4,871",216143,DB00928,Azacitidine
,15851763,area under the curve (AUC(0-infinity)),"Average maximum concentration (C(max)) and area under the curve (AUC(0-infinity)) values increased in a dose-proportionate manner with increasing dose from 10 to 75 mg/m2/d; the mean +/- SD C(max) and AUC(0-infinity) at 10 mg/m2/d were 776 +/- 459 nM and 1,355 +/- 1,125 h*nM, respectively, and at 75 mg/m2/d were 4,871 +/- 1,398 nM and 6,582 +/- 2,560 h*nM, respectively.",Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15851763/),nM,776,216144,DB00928,Azacitidine
,15851763,area under the curve (AUC(0-infinity)),"Average maximum concentration (C(max)) and area under the curve (AUC(0-infinity)) values increased in a dose-proportionate manner with increasing dose from 10 to 75 mg/m2/d; the mean +/- SD C(max) and AUC(0-infinity) at 10 mg/m2/d were 776 +/- 459 nM and 1,355 +/- 1,125 h*nM, respectively, and at 75 mg/m2/d were 4,871 +/- 1,398 nM and 6,582 +/- 2,560 h*nM, respectively.",Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15851763/),h·nM,"1,355",216145,DB00928,Azacitidine
,15851763,area under the curve (AUC(0-infinity)),"Average maximum concentration (C(max)) and area under the curve (AUC(0-infinity)) values increased in a dose-proportionate manner with increasing dose from 10 to 75 mg/m2/d; the mean +/- SD C(max) and AUC(0-infinity) at 10 mg/m2/d were 776 +/- 459 nM and 1,355 +/- 1,125 h*nM, respectively, and at 75 mg/m2/d were 4,871 +/- 1,398 nM and 6,582 +/- 2,560 h*nM, respectively.",Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15851763/),nM,"4,871",216146,DB00928,Azacitidine
,15851763,C(max),"Average maximum concentration (C(max)) and area under the curve (AUC(0-infinity)) values increased in a dose-proportionate manner with increasing dose from 10 to 75 mg/m2/d; the mean +/- SD C(max) and AUC(0-infinity) at 10 mg/m2/d were 776 +/- 459 nM and 1,355 +/- 1,125 h*nM, respectively, and at 75 mg/m2/d were 4,871 +/- 1,398 nM and 6,582 +/- 2,560 h*nM, respectively.",Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15851763/),nM,776,216147,DB00928,Azacitidine
,15851763,AUC(0-infinity),"Average maximum concentration (C(max)) and area under the curve (AUC(0-infinity)) values increased in a dose-proportionate manner with increasing dose from 10 to 75 mg/m2/d; the mean +/- SD C(max) and AUC(0-infinity) at 10 mg/m2/d were 776 +/- 459 nM and 1,355 +/- 1,125 h*nM, respectively, and at 75 mg/m2/d were 4,871 +/- 1,398 nM and 6,582 +/- 2,560 h*nM, respectively.",Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15851763/),h·nM,"1,355",216148,DB00928,Azacitidine
,15851763,AUC(0-infinity),"Average maximum concentration (C(max)) and area under the curve (AUC(0-infinity)) values increased in a dose-proportionate manner with increasing dose from 10 to 75 mg/m2/d; the mean +/- SD C(max) and AUC(0-infinity) at 10 mg/m2/d were 776 +/- 459 nM and 1,355 +/- 1,125 h*nM, respectively, and at 75 mg/m2/d were 4,871 +/- 1,398 nM and 6,582 +/- 2,560 h*nM, respectively.",Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15851763/),h·nM,"6,582",216149,DB00928,Azacitidine
,15851763,terminal half-life,"Despite a short terminal half-life of 1.5 +/- 2.3 hours, inhibition of DNA methyl transferase activity in tumors of patients receiving 5-AC has been documented.",Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15851763/),h,1.5,216150,DB00928,Azacitidine
,31212080,area under the curve (AUC),"On this phase II multicenter study, 63 patients (40 unrelated donors and 23 matched related donors) received a uniform conditioning regimen consisting of fludarabine i.v. (days -7 to -3), BU targeted to a daily area under the curve (AUC) of 4000 μM/min (days -6 to -3) after the administration of a 25-mg/m2 i.v. test dose on 1 day between days -14 to -9, and antithymocyte globulin (days -6, -5, and -4 (2 doses for matched related donors and 3 for matched unrelated donors only).",A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31212080/),[μM] / [min],4000,218958,DB00928,Azacitidine
,31212080,overall survival,"The probability of overall survival at 2 and 5 years was 45.7% (95% CI, 34.9%-59.9%) and 31.2% (95% CI, 21.3% to 45.8%), respectively, for the entire group with a median overall survival of 19.2 months (95% CI, 8.7 to 37.5).",A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31212080/),month,19.2,218959,DB00928,Azacitidine
,31212080,AUC,"In summary, we demonstrated the feasibility of a novel reduced-intensity conditioning regimen with test dose BU targeted to an AUC of 4000 μM/min.",A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31212080/),[μM] / [min],4000,218960,DB00928,Azacitidine
,29471144,intrinsic Km,"To further investigate the absorption of the prodrugs, L-val-DAC was selected and found to be concentration-dependent and saturable, suggesting a carrier-mediated process (intrinsic Km: 7.80 ± 2.61 mM) along with passive transport.",Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29471144/),mM,7.80,228209,DB00928,Azacitidine
,29034009,negativity,MRD negativity at end-induction was 85% in Arm A versus 67% in Arm B patients.,"A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29034009/),,85,230890,DB00928,Azacitidine
,29034009,negativity,MRD negativity at end-induction was 85% in Arm A versus 67% in Arm B patients.,"A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29034009/),,67,230891,DB00928,Azacitidine
,29348128,Overall response rate (ORR),"Overall response rate (ORR) based on an intent-to-treat analysis was 50% (20 complete remissions [CRs], 5 complete remission with incomplete peripheral count recovery, 7 partial remissions [PRs]), with an 8.3-month median duration of remission.","Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29348128/),%,50,241125,DB00928,Azacitidine
less,22160381,peak DAC concentrations,"Oral THU-DAC at a dose that would produce peak DAC concentrations of less than 0.2μM administered 2×/wk for 8 weeks to nonhuman primates was not myelotoxic, hypomethylated DNA in the γ-globin gene promoter, and produced large cumulative increases in fetal hemoglobin.",Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22160381/),μM,0.2,244867,DB00928,Azacitidine
,2578963,elimination t 1/2,"Following 10 or 100 mg/kg i.v., plasma DAC declined in a triexponential manner with an intermediate elimination t 1/2 of 31 min.",Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2'-deoxycytidine with its therapeutic and toxic effects in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2578963/),min,31,266788,DB00928,Azacitidine
,2578963,critical cytotoxic concentration,The critical cytotoxic concentration of DAC appears to be between 0.5 and 1.0 microgram/ml.,Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2'-deoxycytidine with its therapeutic and toxic effects in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2578963/),[μg] / [ml],0.5 and 1.0,266789,DB00928,Azacitidine
,32103148,half-life,Only dry powder 5AZA was detected in brain (~4-h half-life).,5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32103148/),h,4,269788,DB00928,Azacitidine
,26296954,maximum tolerated dose,"Two dose-limiting toxicities were noted in patients with myelodysplastic syndrome at 125 mg/m(2) daily × 5, thus the maximum tolerated dose in patients with myelodysplastic syndrome was 90 mg/m(2) daily × 5.","Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26296954/),mg,90,273319,DB00928,Azacitidine
